In the past years, a great number of new treatments agents have proved effective in the treatment of CLL for different patient groups. New data indicate that not all patient groups benefit in the same manner from immune chemotherapeutic treatments, in this Medtalk Professor Paolo Ghia introduces and provides an overview of the new treatment possibilities, preferred first line treatments and sequence of treatments for different patient groups according to the US and European guidelines.
MEST SETE MEDtalks
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer Se hele webinar
Single-nucleotide polymorphism can aid the prognostics of of patients with idiopathic cytopenia of undetermined significance (ICUS)
In this MEDtalk Stine Mikkelsen present the first study investigating submicroscopic copy number variations/ uniparental disomy in idiopathic cytopenia of undetermined significance patients. In a subset of patients with otherwise no detectable genetic abnormalities, Stine Mikkelsen and colleagues identified structural variations involving genes recurrently affected in MDS. Their results suggest that SNP-A can aid the prognostics of ICUS patients by identifying submicroscopic structural variations as risk markers for poor OS.